EU regulators recommend against renewing approval for GSK's Blenrep
https://seekingalpha.com/news/4046976-eu-regulators-recommend-against-renewing-approval-for-gsks-blenrep?source=feed_sector_healthcare
Dec 15, 2023 - EU regulators have reportedly declined to recommend renewing conditional approval for GSK’s (GSK) blood cancer drug Blenrep. According to Reuters, a European Me
0
GSK (GSK) Beats Stock Market Upswing: What Investors Need to Know
https://www.zacks.com/stock/news/2198311/gsk-gsk-beats-stock-market-upswing-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2198311
Dec 14, 2023 - GSK (GSK) concluded the recent trading session at $36.98, signifying a +0.65% move from its prior day's close.
0
GSK's Jemperli Gets EU Nod for Endometrial Cancer Expanded Use
https://www.zacks.com/stock/news/2196699/gsk-s-jemperli-gets-eu-nod-for-endometrial-cancer-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196699
Dec 12, 2023 - GSK's Jemperli combo receives the European Commission's marketing authorization as a frontline treatment for certain types of primary advanced/recurrent endometrial cancer.
0
GSK Jemperli gets Europe clearance as frontline endometrial cancer therapy
https://seekingalpha.com/news/4045127-gsk-jemperli-gets-europe-clearance-as-frontline-endometrial-cancer-therapy?source=feed_sector_healthcare
Dec 11, 2023 - GSK receives European approval for Jemperli as a frontline immuno-oncology treatment for endometrial cancer, expanding treatment options for patients.
0
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2196150/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2196150
Dec 11, 2023 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
0
Glaxo (GSK) Upgraded to Buy: What Does It Mean for the Stock?
https://www.zacks.com/stock/news/2193139/glaxo-gsk-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2193139
Dec 04, 2023 - Glaxo (GSK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
0
GSK vs. VRTX: Which Stock Should Value Investors Buy Now?
https://www.zacks.com/stock/news/2193083/gsk-vs-vrtx-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2193083
Dec 04, 2023 - GSK vs. VRTX: Which Stock Is the Better Value Option?
0
Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year?
https://www.zacks.com/stock/news/2192952/is-gsk-plc-sponsored-adr-gsk-stock-outpacing-its-medical-peers-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2192952
Dec 04, 2023 - Here is how GSK (GSK) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
0